论文部分内容阅读
本研究探索异基因造血干细胞移植治疗急性非淋巴细胞白血病合并肾细胞癌切除术后患者的有效性与安全性。对1例急性非淋巴细胞白血病合并肾细胞癌患者术后施行了清髓性HLA全相合的异基因外周血造血干细胞移植,预处理方案为全身照射、环磷酰胺及阿糖胞苷,移植物抗宿主病预防方案为环孢霉素A、霉酚酸酯及短程甲氨蝶呤。收集相关临床和随访资料进行分析。结果显示,该患者移植后第16天造血重建,第30天及第100天STR-PCR法检测为完全供者型嵌合,未发生急性或慢性GVHD,无严重并发症,随访44个月无病生存。结论:异基因造血干细胞移植治疗急性非淋巴细胞白血病合并肾细胞癌是可行而有效的。
This study explored the efficacy and safety of allogeneic hematopoietic stem cell transplantation in patients with acute non-lymphocytic leukemia after renal cell carcinoma resection. One case of acute non-lymphocytic leukemia with renal cell carcinoma was treated with myeloablative allogeneic allogeneic peripheral blood stem cell transplantation. The pretreatment protocol was systemic irradiation, cyclophosphamide and cytarabine, Anti-host disease prevention programs are cyclosporin A, mycophenolate mofetil and short-range methotrexate. Collect relevant clinical and follow-up data for analysis. The results showed that hematopoietic reconstitution was performed on the 16th day after transplantation in this patient. On the 30th day and the 100th day, the patients were treated with full-donor chimerism by STR-PCR, without acute or chronic GVHD and without serious complications. The patients were followed up for 44 months Survival Conclusion: Allogeneic hematopoietic stem cell transplantation is feasible and effective in the treatment of acute non-lymphocytic leukemia with renal cell carcinoma.